Step Capital Management Pte. Ltd. Makes New Investment in Tempus AI, Inc. $TEM

Step Capital Management Pte. Ltd. purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 20,000 shares of the company’s stock, valued at approximately $1,181,000. Tempus AI makes up approximately 0.5% of Step Capital Management Pte. Ltd.’s portfolio, making the stock its 16th biggest position.

Other hedge funds have also made changes to their positions in the company. Cranbrook Wealth Management LLC acquired a new stake in Tempus AI in the 3rd quarter worth approximately $25,000. JPL Wealth Management LLC bought a new stake in Tempus AI during the third quarter worth approximately $26,000. GAMMA Investing LLC acquired a new position in Tempus AI during the third quarter valued at approximately $28,000. Harvest Fund Management Co. Ltd bought a new position in shares of Tempus AI in the third quarter valued at approximately $38,000. Finally, Lodestone Wealth Management LLC bought a new position in shares of Tempus AI in the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insiders Place Their Bets

In related news, CFO James William Rogers sold 10,084 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $595,460.20. Following the completion of the transaction, the chief financial officer directly owned 101,166 shares of the company’s stock, valued at $5,973,852.30. This trade represents a 9.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrew Polovin sold 10,949 shares of Tempus AI stock in a transaction on Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the sale, the executive vice president owned 126,918 shares in the company, valued at $7,654,424.58. This represents a 7.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 563,841 shares of company stock valued at $32,258,311 in the last ninety days. 26.27% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Guggenheim decreased their price objective on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. Morgan Stanley dropped their target price on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. HC Wainwright boosted their target price on shares of Tempus AI from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Canaccord Genuity Group decreased their price target on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Finally, BTIG Research lowered their price target on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $75.92.

Tempus AI Stock Performance

Tempus AI stock opened at $47.39 on Monday. The business has a 50 day moving average price of $52.98 and a two-hundred day moving average price of $68.15. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. Tempus AI, Inc. has a 12 month low of $36.22 and a 12 month high of $104.32. The stock has a market cap of $8.47 billion, a price-to-earnings ratio of -33.61 and a beta of 4.90.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.